Explore This Issue
ACEP Now: Vol 38 – No 04 – April 2019The opinions expressed herein are solely those of Dr. Radecki and do not necessarily reflect those of his employer or academic affiliates.
References
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431-441.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study report of andexanet alfa for bleeding associated with factor Xa inhibitors (published online ahead of print Feb. 7, 2019). N Engl J Med. doi:10.1056/NEJMoa1814051.
- Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46.
- Andexxa— an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther. 2018;60(1549):99-101.
- Lu G, Lin JP, Curnutte JT, et al. Effect of andexanet-TFPI interaction on in vitro thrombin formation and coagulation markers in the TF-pathway. Blood. 2017;130(Suppl. 1):629.
- Ansell JE, Bakhru SH, Laulicht BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117(2):238-245.
Pages: 1 2 3 | Single Page
No Responses to “Factor Xa Inhibitor Reversal Agent Is Not Ready for Prime Time”